References
Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–16.
Pershing S, Talwar N, Armenti ST, Grubbs J Jr, Rosenthal JM, Dedania VS, et al. Use of bevacizumab and ranibizumab for wet age-related macular degeneration: influence of CATT results and introduction of aflibercept. Am J Ophthalmol. 2019;207:385–94.
Holtz JK, Thinggaard BS, Grauslund J, Subhi Y. Association between oral metformin use and the risk of age‐related macular degeneration: a systematic review with meta‐analysis. Acta Ophthalmol. 2023;101:595–605.
Grimes KR, Aloney A, Skondra D, Chhablani J. Effects of systemic drugs on the development and progression of age-related macular degeneration. Surv Ophthalmol. 2023;68:332–46.
Glassman AR, Wells JA III, Josic K, Maguire MG, Antoszyk AN, Baker C, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study). Ophthalmology. 2020;127:1201–10.
Lin L-W, Wang S-W, Huang W-C, Huynh TK, Lai C-Y, Ko C-Y, et al. Melatonin inhibits VEGF-induced endothelial progenitor cell angiogenesis in neovascular age-related macular degeneration. Cells. 2023;12:799.
Sobrin L, Susarla G, Stanwyck L, Rouhana JM, Li A, Pollack S, et al. Gene set enrichment analsyes identify pathways involved in genetic risk for diabetic retinopathy. Am J Ophthalmol. 2022;233:111–23.
Léveillard T, Philp NJ, Sennlaub F. Is retinal metabolic dysfunction at the center of the pathogenesis of age-related macular degeneration? Int J Mol Sci. 2019;20:762.
Järgen P, Dietrich A, Herling AW, Hammes H-P, Wohlfart P. The role of insulin resistance in experimental diabetic retinopathy—genetic and molecular aspects. PloS ONE. 2017;12:e0178658.
Sarkar A, Sodha SJ, Junnuthula V, Kolimi P, Dyawanapelly S. Novel and investigational therapies for wet and dry age-related macular degeneration. Drug Discov Today. 2022;27:2322–32.
Chua SY, Welsh P, Sun Z, Balaskas K, Warwick A, Steel D, et al. Associations between HbA1c across the normal range, diagnosed, and undiagnosed diabetes and retinal layer thickness in UK Biobank cohort. Transl Vis Sci Technol. 2023;12:25.
Ramos H, Bogdanov P, Huerta J, Deàs-Just A, Hernández C, Simó R. Antioxidant effects of DPP-4 inhibitors in early stages of experimental diabetic retinopathy. Antioxidants. 2022;11:1418.
Maeda S, Yamagishi S-I, Matsui T, Nakashima S, Ojima A, Maeda S, et al. Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats. Ophthalmic Res. 2013;50:221–6.
Lin W-J, Ma X-F, Hao M, Zhou H-R, Yu X-Y, Shao N, et al. Liraglutide attenuates the migration of retinal pericytes induced by advanced glycation end products. Peptides. 2018;105:7–13.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e263–421.
Author information
Authors and Affiliations
Contributions
Moein Ebrahimi and Sobha Sivaprasad were responsible for conceptualization of the paper, conducting the search, screening potentially eligible studies, updating reference lists, and writing and editing the paper.
Corresponding author
Ethics declarations
Competing interests
SS reported receiving financial support from AbbVie, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, OcuTerra, Roche. SS is also a member of the Eye editorial board. ME has no conflicts of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ebrahimi, M., Sivaprasad, S. The potential effects of newer groups of glucose lowering drugs on age-related macular degeneration. Eye (2024). https://doi.org/10.1038/s41433-024-03066-5
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41433-024-03066-5
- Springer Nature Limited